Cargando…

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

Systemic inflammation is believed to contribute to the distant recurrence of breast cancer. We evaluated serum samples obtained at diagnosis from 249 case:control pairs with stage II-III Her2-negative breast cancer with or without subsequent distant recurrence. Conditional logistic regression analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sparano, Joseph A., O’Neill, Anne, Graham, Noah, Northfelt, Donald W., Dang, Chau T., Wolff, Antonio C., Sledge, George W., Miller, Kathy D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825796/ https://www.ncbi.nlm.nih.gov/pubmed/35136076 http://dx.doi.org/10.1038/s41523-021-00376-9

Ejemplares similares

Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer
por: Rosenberg, Shoshana M., et al.
Publicado: (2022)

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
por: Sparano, Joseph A., et al.
Publicado: (2017)

Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients
por: Huang, Tzu-Ting, et al.
Publicado: (2018)

Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer
por: Obeng‐Gyasi, Samilia, et al.
Publicado: (2020)

Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans
por: Schneider, Bryan P., et al.
Publicado: (2016)

Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer
por: Pennarun, Nicolas, et al.
Publicado: (2022)

Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer
por: Ramani, Vishnu C., et al.
Publicado: (2019)

Genomic alterations of oligodendrogliomas at distant recurrence
por: Liu, Guanzheng, et al.
Publicado: (2023)

Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy
por: Kim, Gina, et al.
Publicado: (2023)

Factitious Disorder in Crohn's Disease: Recurrent Pancytopenia Caused by Surreptitious Ingestion of 6-Mercaptopurine
por: Kahn, Allon, et al.
Publicado: (2015)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
por: Schneider, B P, et al.
Publicado: (2014)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

HER2 gene status in primary breast cancers and matched distant metastases
por: Tapia, Coya, et al.
Publicado: (2007)

Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval
por: Poodt, Ingrid G. M., et al.
Publicado: (2019)

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
por: Adams, Sylvia, et al.
Publicado: (2013)

Weakly supervised temporal model for prediction of breast cancer distant recurrence
por: Sanyal, Josh, et al.
Publicado: (2021)

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
por: Jayasekera, Jinani, et al.
Publicado: (2021)

Distant recurrence risk following early ipsilateral breast tumor recurrence
por: Ishitobi, Makoto, et al.
Publicado: (2017)

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
por: Yang, Hai-Yuan, et al.
Publicado: (2017)

Combining TMEM Doorway Score and Mena(Calc) Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients
por: Ye, Xianjun, et al.
Publicado: (2022)

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
por: Laible, Mark, et al.
Publicado: (2019)

Late Local and Distant Recurrence of Apparently Benign Paraganglioma
por: Singh, Brijesh K, et al.
Publicado: (2022)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
por: Norton, Nadine, et al.
Publicado: (2018)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
por: Schuster, Steven R., et al.
Publicado: (2012)

Differential Prognostic Indicators for Locoregional Recurrence, Distant Recurrence, and Death of Breast Cancer
por: Chairat, Rungnapa, et al.
Publicado: (2013)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
por: Almstedt, Katrin, et al.
Publicado: (2023)

Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis—A Short Bridge between Two Distant Illnesses
por: Secrieru, Alina, et al.
Publicado: (2020)

Author Correction: Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
por: Yang, Hai-Yuan, et al.
Publicado: (2018)

Early calcitonin levels in medullary thyroid carcinoma: Prognostic role in patients without distant metastases at diagnosis
por: Sparano, Clotilde, et al.
Publicado: (2023)

Down-regulation of lncRNA snaR is correlated with postoperative distant recurrence of HPV-negative cervical squamous cell carcinoma
por: Zheng, Zhenli, et al.
Publicado: (2018)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome
por: Guo, Peng, et al.
Publicado: (2017)

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer
por: Ni, Hua, et al.
Publicado: (2021)

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
por: Dieci, M V, et al.
Publicado: (2019)

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
por: Yang, Zheng‐Jun, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3b65b1d2fql9nmdquidqju5379